Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct 15;157(8):1519-1537.
doi: 10.1002/ijc.35523. Epub 2025 Jun 19.

A promising frontier of circulating messenger RNA in liquid biopsy: From mechanisms to clinical applications

Mengqian Li  1 , Yijin Yu  2   3 , Guangyue Liu  4   5 , Shunhong Zhang  5   6 , Chenchen Luo  5   7 , Saidi Hu  5   8 , Siran Wan  5   9 , Linyong Zhao  2   3   5
Affiliations
Review

A promising frontier of circulating messenger RNA in liquid biopsy: From mechanisms to clinical applications

Mengqian Li et al. Int J Cancer. .

Abstract

Liquid biopsy can revolutionize cancer patient management as repeated sampling allows real-time monitoring of disease progression and response to treatment. The circulating transcriptome represents a rich source of potential cancer biomarkers, including coding and non-coding RNAs. As techniques that have enabled us to analyze transcriptome profiling become ever more sophisticated, the great potential of extracellular messenger RNA (mRNA) and intracellular (cellular level) mRNA in liquid biopsy has gradually been realized. In this review, we aim to conclude the mRNA-based liquid biopsy in the tumorous context by illustrating the origins of mRNA markers and scientific findings, and summarizing the advantages of mRNAs over DNA-based liquid biopsy. Besides, we give a glimpse of the application of this strategy in clinical studies and analyze the gap between the bench and bedside. We speculate that mRNAs are a promising frontier of liquid biopsy.

Keywords: cell‐free RNA; circulating tumor cell; extracellular vesicle; liquid biopsy; messenger RNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Analytes for liquid biopsy‐based approaches and types of RNA in liquid biopsy. (A) Liquid biopsy primarily serves as a blood‐based diagnostic tool that analyzes circulating tumor cells, tumor‐derived biomolecules (including circulating tumor DNA, various types of RNA, and metabolites), extracellular vesicles, and tumor‐educated platelets. (B) Tumor‐derived RNAs examined in liquid biopsy mainly consist of messenger RNA (mRNA), microRNA (miRNA), circular RNA (circRNA), long non‐coding RNA (lncRNA), among others.
FIGURE 2
FIGURE 2
Biosources of mRNA and their potential roles in liquid biopsy. (A) Various biofluids, including peripheral blood, blood‐derived components (e.g., plasma, serum), and urine, harbor detectable messenger RNA (mRNA) molecules. (B) In liquid biopsy, mRNA is primarily derived from circulating tumor cells (CTC), extracellular vesicles (EV), tumor‐educated platelets (TEP), and protein‐bound mRNA complexes, such as ribonucleoproteins (RNP). (C) Whole blood and whole urine represent the most extensively studied whole biofluids for mRNA‐based biomarker detection due to their non‐invasive accessibility and rich molecular content. (D) Circulating mRNA profiles offer valuable clinical insights, including identification of response biomarkers and tumor‐associated genomic alterations, prognostic and predictive signatures for therapy response, and elucidation of tumor biology mechanisms. Integrating mRNA analysis with conventional clinical risk factors and other liquid biopsy modalities—such as circulating tumor DNA (ctDNA) and non‐coding RNA (ncRNA)—may enhance diagnostic and monitoring accuracy.
See this image and copyright information in PMC

References

    1. Pal A, Shinde R, Miralles MS, Workman P, de Bono J. Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. Nat Rev Clin Oncol. 2021;18(7):454‐467. - PubMed
    1. Ren F, Fei Q, Qiu K, Zhang Y, Zhang H, Sun L. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation. J Exp Clin Cancer Res. 2024;43(1):96. - PMC - PubMed
    1. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297‐312. - PubMed
    1. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics‐driven oncology. Nat Rev Genet. 2019;20(2):71‐88. - PubMed
    1. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531‐548. - PubMed